An observational study into the usage and efficacy of Crestor 5mg as a start dosage in achieving the LDL-C target level in both statin-naive and treated primary and secondary prevention patients with a high risk of a cardiovascular event.
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals
No locations available